Aug 5, 2026 04:05PM
Jun 9, 2026 12:51PM
Jun 9, 2026 06:51AM
Mar 10, 2026 08:30AM
Oct 17, 2025 07:21AM
Aug 12, 2025 04:05PM
Apr 21, 2025 07:22AM Zevra Therapeutics (ZVRA) Files Definitive Proxy Statement and Mails Letter to Stockholders
Apr 21, 2025 07:22AM
Mar 31, 2025 04:12PM
Mar 31, 2025 04:12PM
Mar 11, 2025 04:05PM
Nov 21, 2024 04:53PM
Nov 21, 2024 04:51PM
Nov 11, 2024 04:40PM Zevra Therapeutics (ZVRA) to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale
Nov 11, 2024 04:36PM
Sep 30, 2024 07:26AM
Sep 24, 2024 07:56AM
Sep 24, 2024 05:40AM
Sep 23, 2024 06:35AM
Sep 20, 2024 12:08PM
Sep 20, 2024 12:08PM Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
Sep 20, 2024 10:14AM
Sep 20, 2024 09:49AM
Sep 6, 2024 10:14AM
Aug 2, 2024 05:50PM
Jul 10, 2024 08:29AM
Jul 9, 2024 02:17PM
Jul 9, 2024 09:06AM Zevra (ZVRA) Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Apr 15, 2024 05:02PM
Apr 15, 2024 05:01PM
Mar 28, 2024 04:32PM
Mar 12, 2024 06:01AM
Mar 4, 2024 07:50AM
Dec 27, 2023 07:33AM
Aug 31, 2023 07:30AM Zevra Therapeutics (ZVRA) to Acquire Acer Therapeutics (ACER)
Jul 19, 2023 07:30AM
Jun 20, 2023 07:31AM
Jun 20, 2023 07:30AM
Jun 13, 2023 07:30AM
Jun 5, 2023 05:54AM
Jun 3, 2023 07:30AM
May 15, 2023 04:05PM Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
May 10, 2023 07:30AM
May 9, 2023 07:30AM
May 8, 2023 07:31AM
May 8, 2023 07:30AM
May 3, 2023 07:32AM
May 3, 2023 07:30AM
Apr 17, 2023 04:05PM Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy
Apr 4, 2023 07:31AM

328,148 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All